Orchestra BioMed Stock (NASDAQ:OBIO)

Revenue Ownership Financials Chart

Previous Close

$4.92

52W Range

$4.22 - $11.69

50D Avg

$6.78

200D Avg

$6.67

Market Cap

$178.53M

Avg Vol (3M)

$128.58K

Beta

0.43

Div Yield

-

OBIO Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

56

IPO Date

Aug 04, 2020

Website

OBIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 23
Product	$654.00K

Fiscal year ends in Dec 23 | Currency in USD

OBIO Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$2.76M	$3.53M	$-782.00K
Operating Income	$-51.51M	$-32.66M	$-21.80M
Net Income	$-49.12M	$-33.61M	$-23.01M
EBITDA	$-51.22M	$-32.44M	$-21.62M
Basic EPS	$-1.48	$-2.24	$-1.13
Diluted EPS	$-1.48	$-2.24	$-1.13

Fiscal year ends in Dec 23 | Currency in USD